Literature DB >> 4586956

Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia.

J W Yates, H J Wallace, R R Ellison, J F Holland.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4586956

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  109 in total

Review 1.  The Evolving AML Genomic Landscape: Therapeutic Implications.

Authors:  Sachi Horibata; George Alyateem; Christin B DeStefano; Michael M Gottesman
Journal:  Curr Cancer Drug Targets       Date:  2020       Impact factor: 3.428

Review 2.  What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction?

Authors:  Priyanka Pophali; Mark Litzow
Journal:  Curr Treat Options Oncol       Date:  2017-01

3.  Prognostic value of the expression of phosphatase and tensin homolog and CD44 in elderly patients with refractory acute myeloid leukemia.

Authors:  Xiao Huang; Dongyun Li; Tiantian Li; B O Zhao; Xinyi Chen
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

Review 4.  Upfront therapy of acute myeloid leukemia.

Authors:  Jenna Vanliere Canzoniero; Bhavana Bhatnagar; Maria R Baer; Ivana Gojo
Journal:  Curr Oncol Rep       Date:  2011-10       Impact factor: 5.075

Review 5.  A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy.

Authors:  R Abraham; R L Basser; M D Green
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

6.  Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study.

Authors:  John F DiPersio; Harry P Erba; Richard A Larson; Selina M Luger; Martin S Tallman; Jeffrey M Brill; Gregoire Vuagniaux; Elisabeth Rouits; J Mel Sorensen; Claudio Zanna
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-03-05

7.  Prediction of clinical outcomes through assessment of sarcopenia and adipopenia using computed tomography in adult patients with acute myeloid leukemia.

Authors:  Jongheon Jung; Eunyoung Lee; Hyoeun Shim; Ju-Hyun Park; Hyeon-Seok Eom; Hyewon Lee
Journal:  Int J Hematol       Date:  2021-03-10       Impact factor: 2.490

8.  Optimum Induction Chemotherapy for Pediatric Acute Myeloid Leukemia: Experience From A Developing Country.

Authors:  Tariq Ghafoor; Shakeel Ahmed; Sumaira Khalil; Tanzeela Farah
Journal:  J Pediatr Pharmacol Ther       Date:  2020

9.  Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia.

Authors:  Daniel J DeAngelo; Alison R Walker; Richard F Schlenk; Jorge Sierra; Bruno C Medeiros; Enrique M Ocio; Christoph Röllig; Stephen A Strickland; Felicitas Thol; Sue-Zette Valera; Kohinoor Dasgupta; Noah Berkowitz; Robert K Stuart
Journal:  Leuk Res       Date:  2019-08-01       Impact factor: 3.156

10.  High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly.

Authors:  Tamjeed Ahmed; Scott Holwerda; Heidi D Klepin; Scott Isom; Leslie R Ellis; Susan Lyerly; Megan Manuel; Sarah Dralle; Dmitriy Berenzon; Bayard L Powell; Timothy S Pardee
Journal:  Leuk Res       Date:  2015-06-01       Impact factor: 3.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.